3-MeO-PCP: Difference between revisions

From TripSit wiki
Jump to navigation Jump to search
No edit summary
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
[[File:3meopcp.jpg|right|3-MeO-PCP in a pill form]]


The effects are often described as more euphoric and mentally clearer than many related compounds.
'''3-Methoxyphencyclidine''' (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
The effects are often described as being more euphoric and mentally clearer than many related compounds.


= History =
== History ==


A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
Line 9: Line 10:
The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.


= Dosage =
== Dosage ==


Use a precise milligram scale to avoid overdosing.
3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.
 
'''Most if not all consumer-grade jewelry-scales advertised as working at the 0.001g (mg) range are not reliably accurate enough to measure quantities weighing less than around 15-25 mg depending on the model and calibration.
With a drug as potent as 3-MeO-PCP a small discrepancy in measurement can make a world of difference in physical and mental response to the dose.
It is for these reasons that it would be in one's best interest to use a [https://wiki.tripsit.me/wiki/Quick_Guide_to_Volumetric_Dosing volumetric dose measurement technique as outlined in this guide.]'''


{| class="wikitable"
{| class="wikitable"
Line 24: Line 29:


| Light || 3-5 mg
| Light || 3-5 mg
|-
| Common || 5-10 mg
|-
| Strong || 10-15 mg
|-
| Heavy || 15-18 mg+
|}
{| class="wikitable"
|+ Insufflated
|-
| Threshold || 1-2 mg
|-
| Light || 2-5 mg


|-
|-
Line 32: Line 63:


| Strong || 8-12 mg
| Strong || 8-12 mg
|-
| Heavy || 12-15 mg+


|}
|}
Line 47: Line 82:
|-
|-


| Total || 4-6 hours
| Total || 3-5 hours +/- 60 minutes, dependent on dose.


|-
|-
Line 55: Line 90:
|}
|}


Insufflated onset is approximately 5-15 minutes and the duration is a bit shorter.
{| class="wikitable"
 
|+ Insufflated


= Effects =
|-


== Postive ==
| Onset || 10-30 minutes
 
|-
 
| Total || 2-4 hours +/- ~30 minutes, dependent on dose.
 
|-
 
| After-effects || 2-48 hours
 
|}
 
== Effects ==
 
=== Positive ===


* Increase in energy / stimulation
* Increase in energy / stimulation
Line 75: Line 126:
* Increased sociability, loss of inhibitions
* Increased sociability, loss of inhibitions


* Closed- and open-eye visuals
* Closed and open-eye visuals


* Shifts in perception of reality
* Shifts in perception of reality


== Neutral ==
=== Neutral ===


* Increased heart rate (lower doses)
* Increased heart rate (lower doses)
Line 97: Line 148:
* Confusion, disorientation
* Confusion, disorientation


== Negative ==
=== Negative ===


* Disturbing hallucinations and/or delusions
* Disturbing hallucinations and/or delusions
Line 115: Line 166:
* Severe distortion or loss of auditory/visual perception
* Severe distortion or loss of auditory/visual perception


= Harm Reduction =
== Harm Reduction ==
 
Do not drive or operate heavy machinery. Take extra precaution if going out in public on 3-MeO-PCP.


== WARNING ==
* 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with [[PCP]]), and as such it has the potential to be very confusing.
* 3-MeO-PCP is considered to be a 'research-chemical', simply meaning that there is little to no clinical data on long-term effects.
* 3-MeO-PCP, as with all arylcyclohexylamine class dissociative compounds may cause neurotoxicity when used frequently or in high dose.
* 3-MeO-PCP acts as a mild Serotonin Reuptake Inhibitor and as such may risk adverse effects as a result of synergy when used with certain serotogenic drugs or medications. See [http://wiki.tripsit.me/wiki/3-MeO-PCP#Interactions Interactions].
* It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See [http://wiki.tripsit.me/wiki/3-MeO-PCP#Dosage the dosage section] for more information.
* 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.


We recommend to have a sober friend with you when taking this substance for the first time.
For more information see [http://wiki.tripsit.me/wiki/Dissociatives#Harm_Reduction Dissociative Harm-Reduction].


== Interactions ==
=== Interactions ===


Check out our [[Drug Combinations]] page and chart for interactions and combinations of common drugs.
Check out our [[Drug Combinations]] page and chart for interactions and combinations of common drugs.
PCP and 3-MeO-PCP have similar profiles and as such its safe to assume the PCP combination-chart data also applies to 3-MeO-PCP.  


Specifically, do not mix with alcohol or benzodiazepines.
Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.


= Chemistry and Pharmacology =
== Chemistry and Pharmacology ==


3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).
3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).
Line 137: Line 192:
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.


= Legal status=
== Legal status ==


UK: Class B, as are all arylcyclohexamines.
UK: Class B, as are all arylcyclohexamines.
Line 143: Line 198:
US: Covered by the analogue act if sold for human consumption.
US: Covered by the analogue act if sold for human consumption.


= Links =
== Links ==


[https://en.wikipedia.org/wiki/3-MeO-PCP Wikipedia]
[https://en.wikipedia.org/wiki/3-MeO-PCP Wikipedia]
Line 154: Line 209:


[[Category:Dissociative]]
[[Category:Dissociative]]
[[category:Research Chemical]]

Latest revision as of 18:11, 14 March 2015

3-MeO-PCP in a pill form
3-MeO-PCP in a pill form

3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical. The effects are often described as being more euphoric and mentally clearer than many related compounds.

History

A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.

Dosage

3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.

Most if not all consumer-grade jewelry-scales advertised as working at the 0.001g (mg) range are not reliably accurate enough to measure quantities weighing less than around 15-25 mg depending on the model and calibration. With a drug as potent as 3-MeO-PCP a small discrepancy in measurement can make a world of difference in physical and mental response to the dose. It is for these reasons that it would be in one's best interest to use a volumetric dose measurement technique as outlined in this guide.

Oral
Threshold 1.5-3 mg
Light 3-5 mg
Common 5-10 mg
Strong 10-15 mg
Heavy 15-18 mg+
Insufflated
Threshold 1-2 mg
Light 2-5 mg
Common 5-8 mg
Strong 8-12 mg
Heavy 12-15 mg+

Duration

Oral
Onset 20-40 minutes
Total 3-5 hours +/- 60 minutes, dependent on dose.
After-effects 2-48 hours
Insufflated
Onset 10-30 minutes
Total 2-4 hours +/- ~30 minutes, dependent on dose.
After-effects 2-48 hours

Effects

Positive

  • Increase in energy / stimulation
  • Euphoria
  • Pleasant mental and/or body high
  • Music appreciation
  • Disconnected thoughts
  • Sense of calm
  • Increased sociability, loss of inhibitions
  • Closed and open-eye visuals
  • Shifts in perception of reality

Neutral

  • Increased heart rate (lower doses)
  • Altered time perception
  • Disrupted speech patterns
  • Analgesia (decreased pain awareness) and numbness
  • Distorted sensory perceptions, hallucinations
  • Unusual and unpredictable behavior
  • Mild to moderate dissociation
  • Confusion, disorientation

Negative

  • Disturbing hallucinations and/or delusions
  • Anxiety, paranoia
  • Severe dissociation, depersonalization
  • Ataxia (loss of motor coordination)
  • Psychotic episodes
  • Nausea, vomiting
  • Temporary amnesia
  • Severe distortion or loss of auditory/visual perception

Harm Reduction

  • 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with PCP), and as such it has the potential to be very confusing.
  • 3-MeO-PCP is considered to be a 'research-chemical', simply meaning that there is little to no clinical data on long-term effects.
  • 3-MeO-PCP, as with all arylcyclohexylamine class dissociative compounds may cause neurotoxicity when used frequently or in high dose.
  • 3-MeO-PCP acts as a mild Serotonin Reuptake Inhibitor and as such may risk adverse effects as a result of synergy when used with certain serotogenic drugs or medications. See Interactions.
  • It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See the dosage section for more information.
  • 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.

For more information see Dissociative Harm-Reduction.

Interactions

Check out our Drug Combinations page and chart for interactions and combinations of common drugs. PCP and 3-MeO-PCP have similar profiles and as such its safe to assume the PCP combination-chart data also applies to 3-MeO-PCP.

Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.

Chemistry and Pharmacology

3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).

3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.

Legal status

UK: Class B, as are all arylcyclohexamines.

US: Covered by the analogue act if sold for human consumption.

Links

Wikipedia

Interview with a Ketamine Chemist

From MXE to PCP